8-K: Pulmatrix Stockholders Approve Cullgen Merger, Reverse Split, Await Key China Regulatory Nod

Pulmatrix, Inc. stockholders have overwhelmingly approved all proposals related to its merger with Cullgen Inc., including a reverse stock split and increased authorized shares, though the merger remains contingent on crucial approval from the China Securities Regulatory Commission.

Summary

• Pulmatrix, Inc. held a special meeting on June 16, 2025, where stockholders voted on proposals related to the merger with Cullgen Inc.
• All seven proposals presented to stockholders were approved by the requisite votes, indicating strong shareholder support for the transaction.
• Key approvals include the issuance of shares of Pulmatrix common stock to Cullgen stockholders, which will represent more than 20% of Pulmatrix's outstanding shares immediately prior to the merger, and the resulting change of control.
• Stockholders also approved an amendment to the company's charter to effect a reverse stock split at a ratio of one new share for every 2 to 10 shares of outstanding common stock.
• An amendment to increase the number of authorized shares of Pulmatrix common stock from 200,000,000 to 250,000,000 was also approved.
• The Cullgen Inc. 2025 Stock Incentive Plan and the Cullgen Inc. 2025 Employee Stock Purchase Plan received stockholder approval.
• Richard Batycky, Ph.D., was elected as a Class II director, although the Pulmatrix board of directors will be reconstituted upon completion of the merger.
• The appointment of CBIZ CPAs P.C. as Pulmatrix's independent registered public accounting firm for fiscal year ending December 31, 2025, was ratified, with Ernst & Young Hua Ming LLP expected to be appointed for that fiscal year if the merger is completed.
• The completion of the merger is still subject to required regulatory approval from the China Securities Regulatory Commission (CSRC), which Pulmatrix has not yet received, introducing a key contingency.

Sentiment

Score: 7

Explanation: The sentiment is generally positive because all shareholder proposals for the merger were approved, indicating strong internal support for the transaction. However, the pending and uncertain China Securities Regulatory Commission (CSRC) approval introduces a notable risk and prevents a higher score.

Positives

• All seven proposals related to the merger with Cullgen Inc. were approved by Pulmatrix stockholders, indicating strong support for the transaction.
• The approval of the reverse stock split provides the company with flexibility to manage its share price and maintain Nasdaq listing compliance.
• The increase in authorized shares provides the Combined Company with flexibility for future capital raises or strategic initiatives.
• Approval of the Cullgen Inc. 2025 Stock Incentive Plan and Employee Stock Purchase Plan supports future employee retention and motivation for the Combined Company.
• The election of Richard Batycky, Ph.D., as a director, and the ratification of the auditor, demonstrate ongoing corporate governance.

Negatives

• The merger's completion is contingent on receiving approval from the China Securities Regulatory Commission (CSRC), which has not yet been obtained.
• There is no assurance that CSRC approval will be received prior to the Merger Agreement's End Date, introducing uncertainty regarding the merger's consummation.
• A significant portion of votes for Proposal No. 1 (Merger Approval) and Proposals No. 4 & 5 (Stock Plans) were "Broker Non-Votes," indicating a lack of instruction from beneficial owners for non-routine matters.

Risks

• Failure to satisfy the remaining conditions to the closing or consummation of the Merger.
• Uncertainty regarding the timing of the consummation of the Merger.
• Failure or delay in obtaining required regulatory approvals, specifically from the China Securities Regulatory Commission (CSRC).
• Risk of the Merger Agreement being terminated prior to closing.
• Potential for adjustments to the exchange ratio, which could alter the ownership percentages of Cullgen and Pulmatrix stockholders in the Combined Company.
• Inability to realize anticipated benefits of the Merger, including future financial and operating results.
• Impact of the Merger on the Combined Company's business relationships, operating results, and general business.
• Challenges in managing expenses and unanticipated spending that could reduce cash resources.
• Inability of the Combined Company to obtain sufficient additional capital to continue to advance its product candidates or its preclinical programs.
• Outcome of any legal proceedings that may be instituted against the Combined Company or any of its directors or officers related to the Merger Agreement or the transactions contemplated thereby.
• Challenges in obtaining, maintaining, and protecting intellectual property rights, particularly those related to its product candidates.
• Inability to advance the development of its product candidates or preclinical activities under the timelines it anticipates in planned and future clinical trials.
• Failure to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates.
• Inability to realize the anticipated benefits of its research and development programs, strategic partnerships, licensing programs or other collaborations.
• Regulatory requirements or developments and the Combined Company's ability to obtain necessary approvals from the U.S. Food and Drug Administration or other regulatory authorities.
• Changes to clinical trial designs and regulatory pathways.
• Competitive responses to the Merger and changes in expected or existing competition.
• Unexpected costs, charges or expenses resulting from the Merger.
• Potential adverse reactions or changes to business relationships resulting from the completion of the Merger.
• Impact of legislative, regulatory, political and economic developments.

Future Outlook

The Combined Company anticipates listing on The Nasdaq Stock Market LLC after the closing of the proposed Merger. The company expects to receive approval from the China Securities Regulatory Commission (CSRC) prior to the End Date of the Merger Agreement, which is a critical condition for the merger's completion. The reverse stock split is expected to adjust the number of outstanding shares, and the new stock incentive and purchase plans are intended to support future employee compensation and retention for the Combined Company.

Management Comments

• Pulmatrix anticipates that it will receive CSRC approval prior to the End Date (as defined in the Merger Agreement), though there can be no assurance this will occur.

Industry Context

This announcement reflects a common strategy in the biopharma industry where smaller companies merge to combine resources, pipelines, and market reach, often involving reverse stock splits to maintain listing compliance and attract broader investor interest. The need for China Securities Regulatory Commission (CSRC) approval highlights the increasing global nature of biopharma transactions, particularly when one entity has significant ties or operations requiring Chinese regulatory oversight.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders (Pulmatrix)**: Their votes approved the merger, which will result in a change of control and a reverse stock split, significantly altering their ownership structure and per-share value. They will become shareholders of the Combined Company.
• **Shareholders (Cullgen)**: Will receive Pulmatrix common stock, becoming shareholders of the Combined Company, subject to the merger's completion.
• **Employees (Combined Company)**: Will benefit from the approved Cullgen Inc. 2025 Stock Incentive Plan and Employee Stock Purchase Plan, providing new equity compensation opportunities.
• **Management (Combined Company)**: The board of directors will be reconstituted upon merger completion, indicating potential changes in leadership structure and roles.

Next Steps

• Obtain approval from the China Securities Regulatory Commission (CSRC) for the merger.
• Complete the merger of PCL Merger Sub, Inc. into Cullgen Inc.
• Reconstitute the Pulmatrix board of directors upon completion of the merger.
• Effectuate the approved reverse stock split of Pulmatrix common stock.
• Appoint Ernst & Young Hua Ming LLP as the Combined Company's independent registered public accounting firm for fiscal year ending December 31, 2025, if the merger is completed.

Key Dates

Keywords

Pulmatrix, Cullgen, Merger, SEC Filing, 8-K, Stockholder Vote, Reverse Stock Split, Corporate Governance, Regulatory Approval, CSRC, Biopharma, Nasdaq Listing, Share Issuance, Change of Control, Stock Incentive Plan, Employee Stock Purchase Plan